News
BMY
42.74
-0.66%
-0.29
TY: Massive Discount, But Variable Distribution Might Not Appeal To Everyone
Tri-Continental Corporation offers exposure to domestic equity securities with a 3.82% yield. The closed-end fund's shares have gained 14.81% over the past five years, underperforming the S&P 500. The fund's portfolio primarily consists of high-yielding dividend stocks and trades at a 12.06% discount to net asset value. The Tri-continental Corporation has a higher yield than the American common equity indices.
Seeking Alpha · 6h ago
BMY Factor-Based Stock Analysis
NASDAQ · 8h ago
3 Healthcare Stocks With The Highest Yields As of June 2024
NASDAQ · 9h ago
Analysts Conflicted on These Healthcare Names: SAGE Therapeutics (SAGE), Bristol-Myers Squibb (BMY) and Cellectis SA (CLLS)
TipRanks · 9h ago
Bristol-Myers Squibb: Could This Be A Value Trap? (Technical Analysis)
Seeking Alpha · 1d ago
Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better
Affimed's recent clinical update on AFM24 means the company has a second viable commercial asset. The stock popped 70% on the news. Acimtamig's update is due before the end of this month. If positive, the company's stock should run again for a possible 3-5x.
Seeking Alpha · 1d ago
Moat Stocks Await Rebound Following May Headwinds
US equities re-initiated their upward trend in May, with markets ending the month higher. The Morningstar Wide Moat Focus Index faced challenges in May due to its equal-weighting, value stock bias and lack of mega-cap tech exposure. The three major US stock indices set new all-time highs in May.
Seeking Alpha · 1d ago
Tracking Baker Brothers Portfolio - Q1 2024 Update
Seeking Alpha · 1d ago
Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
NASDAQ · 2d ago
Weekly Report: what happened at BMY last week (0603-0607)?
Weekly Report · 2d ago
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476M
Structure Therapeutics reports positive clinical results for its obesity drug; raises $476M. Summit Therapeutic expands its rights to Akeso's ivonescimab and raises $200 million in a private placement. Suzhou Alphamab Oncology partners with ArriVent BioPharma to develop antibody drug conjugates.
Seeking Alpha · 3d ago
Bristol Myers: Quality Fundamentals Suppressed By Interest Rates
Seeking Alpha · 3d ago
Bristol Myers Squibb wins antitrust case against insurers regarding generics
Healthcare Bristol Myers Squibb wins antitrust case against insurers regarding generics. A New Jersey federal court sided with the drugmaker in a case brought by health insurers. Plaintiffs included Cigna, Humana, and Blue Cross Blue Shield Association. The drugmaker tried to squelch generic competition for its cancer drugs.
Seeking Alpha · 4d ago
AstraZeneca dominates, Merck’s Keytruda beaten as ASCO 2024 concludes
The annual gathering of the American Society of Clinical Oncology concluded on Monday in Chicago. AstraZeneca (AZN) hogged the limelight with two presentations at ASCO. Summit Therapeutics (SMMT) came from behind to steal the show.
Seeking Alpha · 4d ago
Investing $1 Million In An 8-Fund Portfolio Vs. An All-Stock Portfolio
This article is for income investors who prioritize income over growth. Most retirees and near-term retirees need some form of income in retirement. How much income is enough depends on your spending needs and the age at which you need it. It is important to convert to an income portfolio at least 5-10 years before retirement.
Seeking Alpha · 4d ago
Geron: Innovative Rytelo Enters A Challenging MDS Market
Seeking Alpha · 4d ago
Catalyst Watch: Apple's WWDC, Tesla's annual meeting, Fed's dot plot, and GameStop volatility
Seeking Alpha's Catalyst Watch breaks down next week's key events. Options trading volume has moved higher on Nvidia on Monday. Apple's WWDC conference will dominate attention in the tech sector. The FDA action dates for cancer drugs are expected to arrive next week. OPEC will publish its Monthly Oil Report on June 12.
Seeking Alpha · 5d ago
Halozyme Therapeutics: The Story Brightens
Seeking Alpha · 5d ago
FDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug
FDA approves Geron Corporation's Rytelo for adult patients with transfusion-dependent anemia. The approval covers patients with low-to- intermediate-1 risk myelodysplastic syndromes. In March, the FDA panel voted in favor of the benefits of imetelstat.
Benzinga · 5d ago
More
Webull provides a variety of real-time BMY stock news. You can receive the latest news about Bristol-Myers Squibb Co through multiple platforms. This information may help you make smarter investment decisions.
About BMY
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.